Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target.

Abstract

The disappointingly low survival rate observed in Ewing's sarcoma (ES)/peripheral neuroectodermal tumor (PNET) despite the adoption of aggressive multimodal treatments prompted us to study the existence of autocrine circuits to be used as innovative therapeutic targets. Of the several circuits analyzed, only the insulin-like growth factor receptor (IGF-IR)-mediated loop was found to be constantly present both in cell lines and clinical samples, suggesting a role for this autocrine circuit in the pathogenesis of ES/PNET. The in vitro inhibition of the IGF-IR-mediated circuit by the specific IGF-IR binding antibody alphaIR3 suppressed the growth of ES/PNET cells by decreasing the proliferative rate and increasing apoptosis. alphaIR3 also significantly inhibited the ability of ES/PNET cells to grow in soft agar and to migrate following a chemotactic stimulus. Inactivation of the IGF-IR signaling pathway may therefore be considered as an effective therapeutic modality for patients with ES/PNET.

• Authors: K Scotlandi, S Benini, M Sarti, M Serra, P L Lollini, D Maurici, P Picci, M C Manara, N Baldini
• Journal: Cancer research (Cancer Res) Vol. 56 Issue 20 Pg. 4570-4 (Oct 15 1996) ISSN: 0008-5472 [Print] United States
• PMID: 8840962 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies
• Transforming Growth Factor beta
• Insulin-Like Growth Factor I
• Receptor, IGF Type 1

Topics

• Antibodies (pharmacology)
• Bone Neoplasms (metabolism)
• Cell Movement
• Humans
• Insulin-Like Growth Factor I (metabolism)
• Neuroectodermal Tumors, Primitive, Peripheral (metabolism)
• Receptor, IGF Type 1 (antagonists & inhibitors, metabolism)
• Sarcoma, Ewing (metabolism)
• Transforming Growth Factor beta (metabolism)
• Tumor Cells, Cultured